SX-517
- Generic Name
- SX-517
Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT06228053
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06149481
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 25
- Registration Number
- NCT05604560
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
- Conditions
- Solid TumorsMetastatic Cancer
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT04574583
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination with Nivolumab As a Maintenance Therapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal AdenocarcinomaPancreatic Cancer
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT04477343
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04245397
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸AdventHealth Medical Group & Bone Marrow Transplant at Orlando, Orlando, Florida, United States
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
- Conditions
- Melanoma Stage IIIMelanoma Stage IV
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT03161431
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸MD Anderson, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.